Reduced Blood Clot Risk with Post-hormonal Contraceptives - EMJ

Reduced Blood Clot Risk with Post-hormonal Contraceptives

A RECENT study has revealed that the heightened risk of blood clots associated with hormonal contraceptives significantly diminishes within 2–4 weeks after discontinuation. These contraceptives, which include popular methods such as birth control pills and patches, are known to elevate the risk of blood clots approximately threefold. This study, the first of its kind, provides precise guidance on optimal contraceptive cessation timing, addressing a critical gap in medical knowledge. Combined hormonal contraceptives release oestrogen and progestin to prevent ovulation, and are the most common contraceptives in Europe and North America.

The current study involved collecting blood samples from 66 females on hormonal contraceptives before and after discontinuation, with a control group of 28 females not using hormonal birth control. Clotting markers showed a rapid decline within 1–2 weeks post-discontinuation, normalising by Week 12. This research predominantly involved young, Caucasian, and healthy weight participants. The study used biomarkers associated with combined hormonal contraceptives and clotting activity to assess clotting risk.

These findings have significant implications for discussions surrounding the benefits and risks of hormonal contraceptives. Study author Marc Blondon, University Hospitals of Geneva, Switzerland, suggested that discontinuing contraceptives 2–4 weeks before events that may heighten clotting risk should be sufficient in most cases. “It’s reassuring to know that that possible harm of the pill goes away rapidly when one stops taking it,” was how Blondon summarised their findings. This insight could reshape patient care strategies, and inform broader healthcare guidelines, guiding decisions on when to stop using contraceptives to reduce clotting risk before medical events.

While subgroup analyses did not indicate significant differences across demographics, a larger study is needed to broaden generalisability. Further research is required to confirm a reduction in the risk of actual clotting events.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given